Ashburton Jersey Ltd lessened its holdings in Pfizer Inc. (NYSE:PFE) by 43.8% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 31,750 shares of the biopharmaceutical company’s stock after selling 24,727 shares during the period. Pfizer accounts for approximately 0.6% of Ashburton Jersey Ltd’s portfolio, making the stock its 22nd largest holding. Ashburton Jersey Ltd’s holdings in Pfizer were worth $1,066,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of PFE. Shine Investment Advisory Services Inc. bought a new position in shares of Pfizer during the second quarter valued at about $102,000. Mckinley Capital Management LLC Delaware bought a new position in shares of Pfizer during the second quarter valued at about $103,000. D. Scott Neal Inc. grew its stake in shares of Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC bought a new position in shares of Pfizer during the first quarter valued at about $121,000. Finally, Herndon Capital Management LLC bought a new position in shares of Pfizer during the second quarter valued at about $120,000. Institutional investors own 69.89% of the company’s stock.
In other news, insider Alexander R. Mackenzie sold 14,700 shares of Pfizer stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the transaction, the insider now directly owns 117,432 shares in the company, valued at $4,145,349.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Alexander R. Mackenzie sold 7,350 shares of Pfizer stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $35.65, for a total transaction of $262,027.50. Following the transaction, the executive vice president now owns 117,432 shares of the company’s stock, valued at $4,186,450.80. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by company insiders.
A number of brokerages have recently issued reports on PFE. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective on the stock in a research note on Tuesday, October 3rd. Vetr cut Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price on the stock. in a research note on Wednesday, September 13th. BMO Capital Markets set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Sanford C. Bernstein set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, September 19th. Finally, Deutsche Bank set a $38.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, December 6th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $38.77.
Pfizer Inc. (PFE) traded up $0.68 during trading on Friday, reaching $37.14. The company’s stock had a trading volume of 12,524,254 shares, compared to its average volume of 19,888,109. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. The company has a market cap of $218,400.30, a PE ratio of 14.66, a price-to-earnings-growth ratio of 2.59 and a beta of 1.01. Pfizer Inc. has a fifty-two week low of $30.90 and a fifty-two week high of $36.89.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. During the same period in the previous year, the firm posted $0.61 EPS. The business’s revenue was up .9% on a year-over-year basis. equities analysts forecast that Pfizer Inc. will post 2.59 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Friday, November 10th were issued a dividend of $0.32 per share. The ex-dividend date of this dividend was Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.45%. Pfizer’s payout ratio is 79.01%.
ILLEGAL ACTIVITY NOTICE: “Pfizer Inc. (PFE) Position Lessened by Ashburton Jersey Ltd” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2017/12/15/pfizer-inc-pfe-position-lessened-by-ashburton-jersey-ltd.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.